2024年4月23日 · Chronic myelogenous leukemia (CML) is a type of blood cancer characterized by uncontrolled growth of myeloid cells in the bone marrow. Symptoms of CML may include fatigue, weakness, weight loss ...

2000年3月9日 · The natural history of BCR-ABL-negative CML is characterized by progressive leukemic burden, extramedullary leukemic infiltrates, poor response to chemotherapy, and bone marrow failure. [ 27 , 31 ...

2000年3月9日 · Data from more than 3000 patients treated with allogeneic blood or marrow transplant for CML between 1989 and 1997 was used by the European Group for Blood and Marrow Transplantation (EBMT) to ...

2000年3月9日 · Wednesday, February 19, 2025. News & Perspective Drugs & Diseases CME & Education Video Decision Point Drugs & Diseases CME & Education Video Decision Point

2010年9月24日 · Before imatinib, the median survival for CML was about 4 years, but this has increased dramatically. "In the imatinib era, it is difficult to estimate the median survival, but it certainly appears ...

2000年3月9日 · In these reports, "good-risk" CML patients, based on spleen size, patient age, and peripheral blood eosinophils, basophils, blasts, and platelet count, have an expected median survival of 96-104 ...

March 22, 2011 — Patients with chronic myelogenous leukemia (CML) who are taking imatinib (Gleevec) can expect to live as long as the general population, according to results from a new study ...

2023年6月29日 · Drs Michael J. Mauro and Hagop Kantarjian discuss the cost of chronic myeloid leukemia therapy, long-term safety, adverse events, and the financial toxicity to the patient and the healthcare system.

2024年9月26日 · Chronic Myelogenous Leukemia (CML): 5 Things to Know To Combat Leukemia, Researchers Harness CD37 Chronic Lymphocytic Leukemia: Healthcare Equity in Optimizing Patient Outcomes 0.50 CME / CE ...

2024年12月27日 · Dr Lindsay Rein highlights how new CML data bring important considerations for clinical practice, patient tolerance, and the impact of treatment costs on quality of life.